Phacilitate Leaders World 2019

Phacilitate Leaders World and the World Stem Cell Summit will once again be co-located in Miami.

Cell and Gene Therapy Catapult's Chief Manufacturing Officer, Dr Stephen Ward, and Chief Clinical Officer, Dr Jacqueline Barry will be speaking at this event. 

Wednesday 23 January, 1:30pm
Dr Stephen Ward, Chief Manufacturing Officer
Moving towards globalisation and scale-up of cell therapy GMP manufacturing

Wednesday 23 January, 1:35pm
Dr Jacqueline Barry, Chief Clinical Officer
Roundtable chair: Forging the path to standardised clinical shipments; logistics and delivery of products through multiple silos

Thursday 24 January, 12:30pm
Dr Jacqueline Barry, Chief Clinical Officer
Intelligent logistics - how to secure the final 100 yards

Dr Stephen Ward

Chief Manufacturing Officer

Prior to becoming the new Chief Manufacturing Officer of the Cell and Gene Therapy Catapult Stephen has established the world-class industrialisation capabilities at both the Guy’s Hospital facilities in London, plus designed and built the innovative GMP manufacturing centre in Stevenage.

As the first Chief Operating Officer of CGT Catapult Stephen brings over 25 years of biological medicine research, development and manufacturing experience to the organisation. Stephen enjoys bringing high impact therapies to patients, by developing commercially viable products. Stephen is passionate about securing and growing the cell and gene therapy manufacturing and development supply chain.

He is the current Chair of the BIA’s Manufacturing Advisory Committee, actively promoting and supporting UK biomanufacturing at Government as well as grass root level. His first degree was from the University of Birmingham, and his second degree from the Medical School of Southampton University.

Dr Jacqueline Barry

Chief Clinical Officer

Jacqueline joined Cell and Gene Therapy Catapult as Director of Regulatory Affairs and has since been promoted to Chief Clinical Officer.

Prior to this Jacqueline worked at the Scottish National Blood Transfusion Service in a number of senior regulatory and quality positions, the responsibility for which included designing the regulatory strategy for the Cellular Therapies developed by the Blood Transfusion Service, acting as Responsible Person for Blood and Qualified Person for medicinal product release. Before that she held a number of post-Doctoral academic posts at the University of Edinburgh studying neuromuscular regeneration. She has considerable experience in the development, translation, clinical trial and approval of cell based medicinal products and therapies.

Discover who we are